SOCS1 has been found to be silenced in primary tumors in >50% of hepatocellular carcinoma [14], 44% of gastric carcinoma [15], 75% of melanoma [16], 40% of hepatoblastoma cases, 53–71% of pancreatic cancers and solid tumors, and in 60% of acute myeloid lymphoma [17] and 62% of multiple myeloma [18]. This evidence concerns the gene SOCS1 and hepatocellular carcinoma.